Search

Displaying results 2891 - 2900 of 4344 in total
  1. Drug

    Oxygen

    go.drugbank.com/drugs/DB09140
    ApprovedInvestigationalVet approved

    Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy.

    Products: Sauerstoff medizinisch Siad Austria
  2. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    [A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88]

  3. Drug

    Cloxacillin

    go.drugbank.com/drugs/DB01147
    ApprovedInvestigationalVet approved

    A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.

  4. Drug

    Inecalcitol

    go.drugbank.com/drugs/DB04796
    Investigational

  5. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylc...

  6. Drug

    Panobacumab

    go.drugbank.com/drugs/DB15342
    Investigational

    Panobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).

  7. Drug

    Flunixin

    go.drugbank.com/drugs/DB11518
    ExperimentalVet approved

    Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian.

  8. Drug

    BacTRL-spike

    go.drugbank.com/drugs/DB15811
    Investigational

    The vaccine was developed by Symvivo Corporation. … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids.

  9. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. … According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments

  10. Drug

    R411

    go.drugbank.com/drugs/DB05468
    Experimental

    It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation.